B细胞活化因子/增殖诱导配体系统与系统性红斑狼疮的研究进展

doi:10.3969/j.issn.1007-9572.2017.14.023

摘要/Abstract

摘要： 系统性红斑狼疮（SLE）是一种自身免疫性疾病，其发病机制还不完全明确，现有治疗方法效果也不确切。近年来关于肿瘤坏死因子家族新成员B细胞活化因子（BAFF）及其与SLE发病和SLE临床治疗的研究有较多报道。本文从以下几个方面对相关研究进行综述：BAFF/增殖诱导配体（APRIL）系统的研究进展；BAFF/APRIL系统在SLE发病机制中的作用；BAFF/APRIL系统与SLE不同临床表型的关系和该系统作为疾病活动生物标志物的研究进展；BAFF/APRIL系统与SLE靶向治疗的关系。为进一步开展BAFF/APRIL系统与SLE的研究提供参考。

关键词: 红斑狼疮, 系统性, B细胞活化因子, 增殖诱导配体, 综述

孙天水. B细胞活化因子/增殖诱导配体系统与系统性红斑狼疮的研究进展[J]. 中国全科医学, 2017, 20(14): 1769-1773. DOI: 10.3969/j.issn.1007-9572.2017.14.023.

参考文献

[1] 王海英，鱼云霞，李吴萍.不同年龄系统性红斑狼疮临床特征分析[J].宁夏医科大学学报，2009，31（1）：62-64. DOI：10.3969/j.issn.1674-6309.2009.01.023.

WANG H Y，YU Y X，LI W P.Clinical characteristics of systemic lupus erythematosus in different aged patients[J]. Journal of Ningxia Medical University，2009，31（1）：62-64. DOI：10.3969/j.issn.1674-6309.2009.01.023.

[2] TSOKOS G C.Systemic lupus erythematosus[J].N Engl J Med，2011，365（22）：2110-2121.DOI：10.1056/NEJMra1100359.

[3] PALEY M A, STRAND V, KIM A H.From mechanism to therapies in systemic lupus erythematosus[J].Curr Opin Rheumatol，2017，29（2）：178-186.DOI：10.1097/BOR.0000000000000369.

[4] SCIASCIA S，KHAMASHTA M A，D'CRUZ D P.Targeted therapy in antiphospholipid syndrome[J].Curr Opin Rheumatol，2014，26（3）：269-275.DOI：10.1097/BOR.0000000000000051.

[5] ZOU Y F，XU J H，WANG F，et al.Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus：a prospective cohort study[J].Autoimmunity，2013，46（8）：531-536.DOI：10.3109/08916934.

[6] MACKAY F，WOODCOCK S A，LAWTON P，et al.Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations[J].J Exp Med，1999，190（11）：1697-1710.DOI：10.1084/jem.190.11.1697.

[7] BATTEN M，GROOM J，CACHERO T G，et al.BAFF mediates survival of peripheral immature B lymphocytes[J].J Exp Med，2000，192（10）：1453-1466.DOI：10.1084/jem.192.10.1453.

[8] FURIE R，PETRI M，ZAMANI O，et al.A phase 3，randomized，placebo-controlled study of belimumab，a monoclonal antibody that inhibits BLyS，in patients with systemic lupus erythematosus[J].Arthritis Rheum，2011，63（12）：3918-3930.DOI：10.1002/art.30613.

[9] 刘玉聪，董江萍.治疗红斑狼疮新药：贝利单抗[J].药物评价研究，2011，34（4）：305-310.

LIU Y C，DONG J P.A new drug of SLE treatment：belimumab[J].Drug Evaluation Research，2011，34（4）：305-310.

[10] VINCENT F B，SAULEP-EASTON D，FIGGETT W A，et al.The BAFF/APRIL system：emerging functions beyond B cell biology and autoimmunity[J].Cytokine Growth Factor Rev，2013，24（3）：203-215.DOI：10.1016/j.cytogfr.2013.04.003.

[11] MACKAY F，SCHNEIDER P.Cracking the BAFF code[J].Nat Rev Immunol，2009，9（7）：491-502.DOI：10.1038/nri2572.

[12] GORELIK L，GILBRIDE K，DOBLES M，et al.Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells[J].J Exp Med，2003，198（6）：937-945.DOI：10.1084/jem.20030789.

[13] GOENKA R，MATTHEWS A H，ZHANG B，et al.Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation[J].J Exp Med，2014，211（1）：45-56.DOI：10.1084/jem.20130505.

[14] VINCENT F B，MORAND E F，MACKAY F.BAFF and innate immunity：new therapeutic targets for systemic lupus erythematosus[J].Immunol Cell Biol，2012，90（3）：293-303.DOI：10.1038/icb.2011.111.

[15] MOORE P A，BELVEDERE O，ORR A，et al.BLyS：member of the tumor necrosis factor family and B lymphocyte stimulator[J].Science，1999，285（5425）：260-263.DOI：10.1126/science.285.5425.260.

[16] LIU Y，XU L，OPALKA N，et al.Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands[J].Cell，2002，108（3）：383-394.DOI：10.1016/S0092-8674(02)00631-1.

[17] ZHUKOVSKY E A，LEE J O，VILLEGAS M，et al.TNF ligands：is TALL-1 a trimer or a virus-like cluster?[J].Nature，2004，427（6973）：413-414.DOI：10.1038/427413a.

[18] CACHERO T G，SCHWARTZ I M，QIAN F，et al.Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF（B cell activating factor）[J].Biochemistry，2006，45（7）：2006-2013.DOI：10.1021/bi051685o.

[19] BOSSEN C，CACHERO T G，TARDIVEL A，et al.TACI，unlike BAFF-R，is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts[J].Blood，2008，111（3）：1004-1012.DOI： 10.1182/blood-2007-09-110874.

[20] GAVIN A L，DUONG B，SKOG P，et al.DeltaBAFF，a splice isoform of BAFF，opposes full-length BAFF activity in vivo in transgenic mouse models[J].J Immunol，2005，175（1）：319-328.

[21] GAVIN A L，AÏT-AZZOUZENE D，WARE C F，et al.DeltaBAFF，an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine，BAFF[J].J Biol Chem，2003，278（40）：38220-38228.DOI：10.1074/jbc.M306852200.

[22] STOHL W.Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus[J].Expert Opin Ther Targets，2014，18（4）：473-489.DOI：10.1517/14728222.2014.888415.

[23] PANCHANATHAN R，CHOUBEY D.Murine BAFF expression is up-regulated by estrogen and interferons：implications for sex bias in the development of autoimmunity[J].Mol Immunol，2013，53（1/2）：15-23.DOI：10.1016/j.molimm.2012.06.013.

[24] ABU-RISH E Y，AMRANI Y，BROWNING M J.Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor（BAFF） on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF[J].Rheumatology（Oxford），2013，52（7）：1190-1201.DOI：10.1093/rheumatology/ket006.

[25] NARDELLI B，BELVEDERE O，ROSCHKE V，et al.Synthesis and release of B-lymphocyte stimulator from myeloid cells[J].Blood，2001，97（1）：198-204.

[26] KIM H A，JEON S H，SEO G Y，et al.TGF-beta1 and IFN-gamma stimulate mouse macrophages to express BAFF via different signaling pathways[J].J Leukoc Biol，2008，83（6）：1431-1439.DOI：10.1189/jlb.1007676.

[27] USLU K，COLEMAN A S，ALLMAN W R，et al.Impaired B cell receptor signaling is responsible for reduced TACI expression and function in X-linked immunodeficient mice[J].J Immunol，2014，192（8）：3582-3595.DOI：10.4049/jimmunol.1203468.

[28] PRADET-BALADE B，MEDEMA J P，LÓPEZ-FRAGA M，et al.An endogenous hybrid mRNA encodes TWE-PRIL，a functional cell surface TWEAK-APRIL fusion protein[J].EMBO J，2002，21（21）：5711-5720.

[29] INGOLD K，ZUMSTEG A，TARDIVEL A，et al.Identification of proteoglycans as the APRIL-specific binding partners[J].J Exp Med，2005，201（9）：1375-1383.DOI：10.1084/jem.20042309.

[30] KIMBERLEY F C，VAN BOSTELEN L，CAMERON K，et al.The proteoglycan（heparan sulfate proteoglycan）binding domain of APRIL serves as a platform for ligand multimerization and cross-linking[J].FASEB J，2009，23（5）：1584-1595.DOI：10.1096/fj.08-124669.

[31] SINDHAVA V J，SCHOLZ J L，STOHL W，et al.APRIL mediates peritoneal B-1 cell homeostasis[J].Immunol Lett，2014，160（2）：120-127.DOI：10.1016/j.imlet.2014.01.018.

[32] DILLON S R，HARDER B，LEWIS K B，et al.B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin[J].Arthritis Res Ther，2010，12（2）：R48.DOI：10.1186/ar2959.

[33] ROSCHKE V，SOSNOVTSEVA S，WARD C D，et al.BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases[J].J Immunol，2002，169（8）：4314-4321.

[34] JACOB C O，GUO S，JACOB N，et al.Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice[J].Arthritis Rheum，2012，64（5）：1610-1619.DOI：10.1002/art.33458.

[35] DAVIDSON A.Targeting BAFF in autoimmunity[J].Curr Opin Immunol，2010，22（6）：732-739.DOI：10.1016/j.coi.2010.09.010.

[36] TSUJI S，CORTESÃO C，BRAM R J，et al.TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow[J].Blood，2011，118（22）：5832-5839.DOI：10.1182/blood-2011-05-353961.

[37] OU X，XU S，LAM K P.Deficiency in TNFRSF13B（TACI）expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival[J].Proc Natl Acad Sci U S A，2012，109（38）：15401-15406.DOI：10.1073/pnas.1200386109.

[38] TREML L S，CARLESSO G，HOEK K L，et al.TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells[J].J Immunol，2007，178（12）：7531-7539.

[39] CASTIGLI E，WILSON S A，ELKHAL A，et al.Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation[J].J Allergy Clin Immunol，2007，120（4）：885-891.DOI：10.1016/j.jaci.2007.06.012.

[40] 王东建，苏励，王骁，等.不同体质MRL/lpr狼疮鼠B淋巴细胞刺激因子及其受体基因及蛋白质的表达[J].北京中医药大学学报，2015，38（9）：619-623.DOI：10.3969/j.issn.1006-2157.2015.09.009.

WANG D J，SU L，WANG X，et al.Gene and protein expression of B cell-activating factor and its receptor in MRL/lpr lupus mice with different constitutions[J].Journal of Beijing University of Traditional Chinese Medicine，2015，38（9）：619-623. DOI：10.3969/j.issn.1006-2157.2015.09.009.

[41] FU L，LIN-LEE Y C，PHAM L V，et al.BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells[J].Blood，2009，113（19）：4627-4636.DOI：10.1182/blood-2008-10-183467.

[42] MECKLENBRÄUKER I，KALLED S L，LEITGES M，et al.Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signaling[J].Nature，2004，431（7007）：456-461.DOI：10.1038/nature02955.

[43] LIU D，LI P，SONG S，et al.Pro-apoptotic effect of epigallo-catechin-3-gallate on B lymphocytes through regulating BAFF/PI3K/Akt/mTOR signaling in rats with collagen-induced arthritis[J].Eur J Pharmacol，2012，690（1/3）：214-225.DOI：10.1016/j.ejphar.2012.06.026.

[44] LIANG D，ZENG Q，XU Z，et al.BAFF activates Erk1/2 promoting cell proliferation and survival by Ca2+-CaMKII-dependent inhibition of PP2A in normal and neoplastic B-lymphoid cells[J].Biochem Pharmacol，2014，87（2）：332-343.DOI：10.1016/j.bcp.2013.11.006.

[45] JELLUSOVA J，MILETIC A V，CATO M H，et al.Context-specific BAFF-R signaling by the NF-κB and PI3K pathways[J].Cell Rep，2013，5（4）：1022-1035.DOI：10.1016/j.celrep.2013.10.022.

[46] BOSSEN C，TARDIVEL A，WILLEN L，et al.Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses[J].Eur J Immunol，2011，41（3）：787-797.DOI：10.1002/eji.201040591.

[47] GROSS J A，JOHNSTON J，MUDRI S，et al.TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease[J].Nature，2000，404（6781）：995-999.DOI：10.1038/35010115.

[48] SMITH C K，KAPLAN M J.The role of neutrophils in the pathogenesis of systemic lupus erythematosus[J].Curr Opin Rheumatol，2015，27（5）：448-453.DOI：10.1097/BOR.0000000000000197.

[49] COQUERY C M，WADE N S，LOO W M，et al.Neutrophils contribute to excess serum BAFF levels and promote CD4+ T cell and B cell responses in lupus-prone mice[J].PLoS One，2014，9（7）：e102284.DOI：10.1371/journal.pone.0102284.

[50] LESLEY R，XU Y，KALLED S L，et al.Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF[J].Immunity，2004，20（4）：441-453.

[51] THIEN M，PHAN T G，GARDAM S，et al.Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches[J].Immunity，2004，20（6）：785-798.DOI：10.1016/j.immuni.2004.05.010.

[52] FAIRFAX K A，TSANTIKOS E，FIGGETT W A，et al.BAFF-driven autoimmunity requires CD19 expression[J].J Autoimmun，2015，62：1-10.DOI：10.1016/j.jaut.2015.06.001.

[53] GROOM J R，FLETCHER C A，WALTERS S N，et al.BAFF and MyD88 signals promote a lupuslike disease independent of T cells[J].J Exp Med，2007，204（8）：1959-1971.DOI：10.1084/jem.20062567.

[54] FIGGETT W A，FAIRFAX K，VINCENT F B，et al.The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death[J].Immunity，2013，39（3）：573-583.DOI：10.1016/j.immuni.2013.05.019.

[55] NICOLETTI A M，HESS KENNY C，KHALIL A M，et al.Unexpected potency differences between BAFF antagonist antibodies against various forms of BAFF[J].J Pharmacol Exp Ther，2016，359(1)：37-44.DOI： 10.1124/jpet.116.236075.

[56] STOHL W，BANFALVI A.B cell-independent contribution of BAFF to murine autoimmune disease[J].Clin Immunol，2016，172：111-116.DOI：10.1016/j.clim.2016.07.009.

[57] RÖNNBLOM L.Potential role of IFNα in adult lupus[J].Arthritis Res Ther，2010，12（Suppl 1）：S3.DOI：10.1186/ar2884.

[58] LÖVGREN T，ELORANTA M L，BÅVE U，et al.Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG[J].Arthritis Rheum，2004，50（6）：1861-1872.DOI：10.1002/art.20254.

[59] RANA A，MINZ R W，AGGARWAL R，et al.Gene expression of cytokines（TNF-α，IFN-γ），serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus[J].Lupus，2012，21（10）：1105-1112.DOI：10.1177/0961203312451200.

[60] BENNETT L，PALUCKA A K，ARCE E，et al.Interferon and granulopoiesis signatures in systemic lupus erythematosus blood[J].J Exp Med，2003，197（6）：711-723.DOI：10.1084/jem.20021553.

[61] SJÖSTRAND M，JOHANSSON A，AQRAWI L，et al.The expression of BAFF is controlled by IRF transcription factors[J].J Immunol，2016，196（1）：91-96.DOI：10.4049/jimmunol.1501061.

[62] LITINSKIY M B，NARDELLI B，HILBERT D M，et al.DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL[J].Nat Immunol，2002，3（9）：822-829.DOI：10.1038/ni829.

[63] CERUTTI A，COLS M，PUGA I.Marginal zone B cells：virtues of innate-like antibody-producing lymphocytes[J].Nat Rev Immunol，2013，13（2）：118-132.DOI：10.1038/nri3383.

[64] WANG J H，NEW J S，XIE S，et al.Extension of the germinal center stage of B cell development promotes autoantibodies in BXD2 mice[J].Arthritis Rheum，2013，65（10）：2703-2712.DOI：10.1002/art.38059.

[65] YAO Y，RICHMAN L，HIGGS B W，et al.Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus[J]. Arthritis Rheum，2009，60（6）：1785-1796.DOI：10.1002/art.24557.

[66] JACOB N，GUO S，MATHIAN A，et al.B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice[J].J Immunol，2011，186（8）：4984-4993.DOI：10.4049/jimmunol.1000466.

[67]BLANCO P，PALUCKA A K，GILL M，et al.Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus[J].Science，2001，294(5546)：1540-1543.DOI：10.1126/science.1064890.

[68] JOO H，COQUERY C，XUE Y，et al.Serum from patients with SLE instructs monocytes to promote IgG and IgA plasmablast differentiation[J].J Exp Med，2012，209（7）：1335-1348.DOI：10.1084/jem.20111644.

[69] HUARD B，TRAN N L，BENKHOUCHA M，et al.Selective APRIL blockade delays systemic lupus erythematosus in mouse[J].PLoS One，2012，7（2）：e31837.DOI：10.1371/journal.pone.0031837.

[70] GINZLER E M，WAX S，RAJESWARAN A，et al.Atacicept in combination with MMF and corticosteroids in lupus nephritis：results of a prematurely terminated trial[J].Arthritis Res Ther，2012，14（1）：R33.DOI：10.1186/ar3738.

[71] SALAZAR-CAMARENA D C，ORTIZ-LAZARENO P C，CRUZ A，et al.Association of BAFF，APRIL serum levels，BAFF-R，TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus[J].Lupus，2016，25（6）：582-592.DOI：10.1177/0961203315608254.

[72] JIANG C，LOO W M，GREENLEY E J，et al.B cell maturation antigen deficiency exacerbates lymphoproliferation and autoimmunity in murine lupus[J].J Immunol，2011，186（11）：6136-6147.DOI：10.4049/jimmunol.1001931.

[73] JACOB C O，YU N，GUO S，et al.Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor[J].Arthritis Rheum，2013，65（4）：1043-1054.DOI：10.1002/art.37846.

[74] HE B，SANTAMARIA R，XU W，et al.The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88[J].Nat Immunol，2010，11（9）：836-845.DOI：10.1038/ni.1914.

[75] MEYERS G，NG Y S，BANNOCK J M，et al.Activation-induced cytidine deaminase（AID）is required for B-cell tolerance in humans[J].Proc Natl Acad Sci U S A，2011，108（28）：11554-11559.DOI：10.1073/pnas.1102600108.

[76] HOFFMANN F S，KUHN P H，LAURENT S A，et al.The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity[J].J Immunol，2015，194（2）：542-552.DOI：10.4049/jimmunol.1402070.

[77] LA CAVA A.Common variable immunodeficiency：two mutations are better than one[J].J Clin Invest，2013，123（10）：4142-4143.DOI：10.1172/JCI72476.

[78] MARTINEZ-GALLO M，RADIGAN L，ALMEJÚN M B，et al.TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes[J].J Allergy Clin Immunol，2013，131（2）：468-476.DOI：10.1016/j.jaci.2012.10.029.

[79] JACOB C O，YU N，SINDHAVA V，et al.Differential development of systemic lupus erythematosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors[J].Arthritis Rheumatol，2015，67（9）：2523-2535.DOI：10.1002/art.39210.

[80] ZHANG L，ZHENG S，WU H，et al.Identification of BLyS（B lymphocyte stimulator），a non-myelin-associated protein，as a functional ligand for Nogo-66 receptor[J].J Neurosci，2009，29（19）：6348-6352.DOI：10.1523/JNEUROSCI.5040-08.2009.

[81] KRUMBHOLZ M，THEIL D，DERFUSS T，et al.BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma[J].J Exp Med，2005，201（2）：195-200.DOI: 10.1084/jem.20041674.

[82] VINCENT F B，NORTHCOTT M，HOI A，et al.Association of serum B cell activating factor from the tumour necrosis factor family（BAFF）and a proliferation-inducing ligand（APRIL） with central nervous system and renal disease in systemic lupus erythematosus[J].Lupus，2013，22（9）：873-884.DOI：10.1177/0961203313496302.

[83] GEORGE-CHANDY A，TRYSBERG E，ERIKSSON K.Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus：relationship to neuropsychiatric symptoms[J].Arthritis Res Ther，2008，10（4）：R97.DOI：10.1186/ar2484.

[84] VINCENT F B，BOURKE P，MORAND E F，et al.Focus on systemic lupus erythematosus in indigenous Australians：towards a better understanding of autoimmune diseases[J].Intern Med J，2013，43（3）：227-234.DOI：10.1111/imj.12039.

[85] BORCHERS A T，NAGUWA S M，SHOENFELD Y，et al.The geoepidemiology of systemic lupus erythematosus[J]. Autoimmun Rev，2010，9（5）：A277-287.DOI：10.1016/j.autrev.2009.12.008.

[86] CERVERA R，DORIA A，AMOURA Z，et al.Patterns of systemic lupus erythematosus expression in Europe[J].Autoimmun Rev，2014，13（6）：621-629.DOI：10.1016/j.autrev.2013.11.007.

[87] RITTERHOUSE L L，CROWE S R，NIEWOLD T B，et al.B lymphocyte stimulator levels in systemic lupus erythematosus：higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels[J].Arthritis Rheum，2011，63（12）：3931-3941.DOI：10.1002/art.30598.

[88] KAWASAKI A，TSUCHIYA N，FUKAZAWA T，et al.Analysis on the association of human BLYS（BAFF，TNFSF13B）polymorphisms with systemic lupus erythematosus and rheumatoid arthritis[J].Genes Immun，2002，3（7）：424-429.DOI：10.1038/sj.gene.6363923.

[89] ZAYED R A，SHEBA H F，ABO ELAZAEM M A，et al.B-cell activating factor promoter polymorphisms in egyptian patients with systemic lupus erythematosus[J].Ann Clin Lab Sci，2013，43（3）：289-294.

[90] KAWASAKI A，TSUCHIYA N，OHASHI J，et al.Role of APRIL（TNFSF13）polymorphisms in the susceptibility to systemic lupus erythematosus in Japanese[J].Rheumatology（Oxford），2007，46（5）：776-782.DOI：10.1093/rheumatology/kem019.

[91] FURUYA T，KOGA M，HIKAMI K，et al.Effects of APRIL （TNFSF13）polymorphisms and splicing isoforms on the secretion of soluble APRIL[J].Mod Rheumatol，2012，22（4）：541-549.DOI：10.1007/s10165-011-0539-z.

[92] KOYAMA T，TSUKAMOTO H，MASUMOTO K，et al.A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus[J].Rheumatology（Oxford），2003，42（8）：980-985.DOI：10.1093/rheumatology/keg270.

[93] LEE Y H，OTA F，KIM-HOWARD X，et al.APRIL polymorphism and systemic lupus erythematosus（SLE）susceptibility[J].Rheumatology（Oxford），2007，46（8）：1274-1276.DOI：10.1093/rheumatology/kem093.

[94] 常文静，蔡辉.系统性红斑狼疮相关的生物标志物[J].国际检验医学杂志，2014，23（20）：2796-2799.DOI：10.3969/j.issn.1673-4130.2014.20.034.

CHANG W J，CAI H.Systemic lupus erythematosus related biomarkers[J].International Journal of Laboratory Medicine，2014，23（20）：2796-2799. DOI：10.3969/j.issn.1673-4130.2014.20.034.

[95] PETRI M A，VAN VOLLENHOVEN R F，BUYON J，et al.Baseline predictors of systemic lupus erythematosus flares：data from the combined placebo groups in the phase Ⅲ belimumab trials[J].Arthritis Rheum，2013，65（8）：2143-2153.DOI：10.1002/art.37995.

[96] CARTER L M，ISENBERG D A，EHRENSTEIN M R.Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus[J].Arthritis Rheum，2013，65（10）：2672-2679.DOI：10.1002/art.38074.

[97] 温斯健，林有坤，吴玲艳，等.B淋巴细胞刺激因子及其受体与系统性红斑狼疮的相关性研究[J].广西医学，2014，36（3）：281-284.DOI：10.11675/j.issn.0253-4304.2014.03.03.

WEN S J，LIN Y K，WU L Y，et al.Correlation of B lymphocyte stimulator and its receptor with systemic lupus erythematosus[J].Guangxi Medical Journal，2014，36（3）：281-284. DOI：10.11675/j.issn.0253-4304.2014.03.03.

[98] STOHL W，HIEPE F，LATINIS K M，et al.Belimumab reduces autoantibodies，normalizes low complement levels，and reduces select B cell populations in patients with systemic lupus erythematosus[J].Arthritis Rheum，2012，64（7）：2328-2337.DOI：10.1002/art.34400.

[99] LE POTTIER L，BENDAOUD B，RENAUDINEAU Y，et al.New ELISA for B cell-activating factor[J].Clin Chem，2009，55（10）：1843-1851.DOI：10.1373/clinchem.2009.129940.

[100] CHEEMA G S，ROSCHKE V，HILBERT D M，et al.Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases[J].Arthritis Rheum，2001，44（6）：1313-1319.DOI：10.1002/1529-0131(200106)44:63.0.CO；2-S.

[101] PETRI M，STOHL W，CHATHAM W，et al.Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus[J].Arthritis Rheum，2008，58（8）：2453-2459.DOI：10.1002/art.23678.

[102] DUAN J H，JIANG Y，MU H，et al.Expression of BAFF and BR3 in patients with systemic lupus erythematosus[J].Braz J Med Biol Res，2016，49（3）.pii：S0100-879X2016000300706.DOI：10.1590/1414-431X20154853.

[103] ZOLLARS E，BIENKOWSKA J，CZERKOWICZ J，et al.BAFF（B cell activating factor）transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year[J].Lupus Sci Med，2015，2（1）：e000063.DOI：10.1136/lupus-2014-000063.

[104] 郭文静，陈琳洁，李志军，等.系统性红斑狼疮患者外周血浆细胞样树突状细胞的变化及意义[J].蚌埠医学院学报，2016，41（8）：995-999.DOI：10.13898/j.cnki.issn.1000-2200.2016.08.005.

GUO W J，CHEN L J，LI Z J，et al.The change of plasmacytoid dendritic cells in peripheral blood of systemic lupus erythematosus patients and its significance[J].Journal of Bengbu Medical College，2016，41（8）：995-999. DOI：10.13898/j.cnki.issn.1000-2200.2016.08.005.

[105] CHATHAM W W，WALLACE D J，STOHL W，et al.Effect of belimumab on vaccine antigen antibodies to influenza，pneumococcal，and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial[J].J Rheumatol，2012，39（8）：1632-1640.DOI：10.3899/jrheum.111587.

[106] VAN VOLLENHOVEN R F，PETRI M A，CERVERA R，et al.Belimumab in the treatment of systemic lupus erythematosus：high disease activity predictors of response[J].Ann Rheum Dis，2012，71（8）：1343-1349.DOI：10.1136/annrheumdis-2011-200937.

[107] FURER V，ZISMAN D，POKROY-SHAPIRA E，et al.Systemic lupus erythematosus exacerbation following cessation of belimumab treatment[J].Scand J Rheumatol，2016，45（2）：103-106.DOI：10.3109/03009742.2015.1074277.

[108] DOOLEY M A，HOUSSIAU F，ARANOW C，et al.Effect of belimumab treatment on renal outcomes：results from the phase 3 belimumab clinical trials in patients with SLE[J].Lupus，2013，22（1）：63-72.DOI：10.1177/0961203312465781.

[109] FRIERI M，HEUSER W，BLISS J.Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis[J].J Pharmacol Pharmacother，2015，6（2）：71-76.DOI：10.4103/0976-500X.155482.

[110] FIGGETT W A，DELIYANTI D，FAIRFAX K A，et al.Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers[J].J Autoimmun，2015，61：9-16.DOI：10.1016/j.jaut.2015.04.007.

[111] WITCHER J，FLEISCHMANN R，CHINDALORE V L，et al.Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus[J].Br J Clin Pharmacol，2016，81（5）：908-917.DOI：10.1111/bcp.12860.

[112] ISENBERG D A，PETRI M，KALUNIAN K，et al.Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus：results from ILLUMINATE-1，a 52-week，phase Ⅲ，multicentre，randomised，double-blind，placebo-controlled study[J].Ann Rheum Dis，2016，75（2）：323-331.DOI：10.1136/annrheumdis-2015-207653.

[113] TANAKA Y，TAKEUCHI T，AKASHI N，et al.Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus：Subgroup analyses of the ILLUMINATE-1 study[J].Mod Rheumatol，2016，29：1-8.DOI：10.1080/14397595.2016.1206260.

[114] HSU H，KHARE S D，LEE F，et al.A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease[J].Clin Exp Rheumatol，2012，30（2）：197-201.

[115] SCHEINBERG M A，HISLOP C M，MARTIN R S.Blisibimod for treatment of systemic lupus erythematosus：with trials you become wiser[J].Expert Opin Biol Ther，2016，16（5）：723-733.DOI：10.1517/14712598.2016.1169270.

[116] KAYAGAKI N，YAN M，SESHASAYEE D，et al.BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2[J].Immunity，2002，17（4）：515-524.

[117] 马宁.BAFF抑制自身免疫性疾病中IL-15表达的作用机制研究[D].吉林：吉林大学，2015. MA N.The mechanism by which BAFF suppresses IL-15 expression in autoimmune diseases[D].Jilin：Jilin University，2015.

[118] COGOLLO E，SILVA M A，ISENBERG D.Profile of atacicept and its potential in the treatment of systemic lupus erythematosus[J].Drug Des Devel Ther，2015，9：1331-1339.DOI：10.2147/DDDT.S71276.

[119] JI J，XU J，LI F，et al.A benzenediamine derivate FC-99 attenuates lupus nephritis in MRL/lpr mice via inhibiting myeloid dendritic cell-secreted BAFF[J].Acta Biochim Biophys Sin（Shanghai），2016，48（5）：411-419.DOI：10.1093/abbs/gmw017.

[120] EHRENSTEIN M R，WING C.The BAFFling effects of rituximab in lupus：danger ahead?[J].Nat Rev Rheumatol，2016，12（6）：367-372.DOI：10.1038/nrrheum.2016.18.

[121] LIN W，SESHASAYEE D，LEE W P，et al.Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus[J].Arthritis Rheumatol，2015，67（1）：215-224.DOI：10.1002/art.38907.

[122] WU D H，XU L，WEN C P，et al.The effects of Jieduquyuzishen prescription-treated rat serum on the BAFF/BAFF-R signal pathway[J].PLoS One，2015，10（2）：e0118462.DOI：10.1371/journal.pone.0118462.

[123] 涂学君.糖皮质激素对狼疮性肾炎患者活动性作用与肾内B淋巴细胞刺激因子的相关性[J].齐齐哈尔医学院学报，2016，37（12）：1514-1516. TU X J.Study of correlation between glucocorticoid for lupus nephritis active role and renal B lymphocyte stimulator[J].Journal of Qiqihar University of Medicine，2016，37（12）：1514-1516.

[124] FENG G D，XUE X C，GAO M L，et al.Therapeutic effects of PADRE-BAFF autovaccine on rat adjuvant arthritis[J]. Biomed Res Int，2014，2014：854954.DOI：10.1155/2014/854954.

[125] ROSARIO C，SEGURO L，VASCONCELOS C，et al.Is there a cure for systemic lupus erythematosus?[J].Lupus，2013，22（5）：417-421.DOI：10.1177/0961203313479839.

[126] PETRI M，WALLACE D J，SPINDLER A，et al.Sifalimumab，a human anti-interferon-α monoclonal antibody，in systemic lupus erythematosus：a phase I randomized，controlled，dose-escalation study[J].Arthritis Rheum，2013，65（4）：1011-1021.DOI：10.1002/art.37824.

[127] LAUWERYS B R，HACHULLA E，SPERTINI F，et al.Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid[J].Arthritis Rheum，2013，65（2）：447-456.DOI：10.1002/art.37785.